£13.9M
The financing round was backed by BGF, Parkwalk, and Meltwind to drive therapeutics discovery in autoimmune and other common diseases.
Enhanced Genomics
Biotechnology company pioneering 3D multi-omics to identify drug targets for common diseases.
£13.9MTotal raised
Enhanced Genomics operates a proprietary 3D multi-omics platform that maps genome-wide interactions to identify genetically validated drug targets for common diseases. The Cambridge-based biotechnology firm aims to accelerate pharmaceutical development and improve clinical success rates.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Net assets
Members only
Fixed assets
Members only
Current assets
Members only
Employees
Members only
Cash, assets and headcount from Enhanced Genomics's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Team
DS
Dietrich Stephan
Chair